DUBLIN, Ireland--(BUSINESS WIRE)--Sep. 18, 2014-- Covidien plc (NYSE:COV) today announced the expansion of its Sonicision™ Cordless Ultrasonic Dissection Device portfolio, following U.S. Food and Drug Administration 510(k) clearance of three additional device lengths: 13 cm, 26 cm, and 48 cm. With the most versatile cordless ultrasonic portfolio in the industry, Covidien now offers surgeons more options when performing pediatric, urological and bariatric procedures on patients of all sizes.

The U.S. Food and Drug Administration cleared three new device shaft lengths in addition to the current 39 cm device. Covidien’s Sonicision™ Cordless Ultrasonic Dissection Device portfolio consists of: 13 cm, 26 cm, 39 cm and 48 cm. (Photo: Business Wire)

“Covidien is a pioneer in developing energy-based medical devices and the Sonicision system’s groundbreaking cordless technology continues to transform how minimally invasive surgery is performed,” said Chris Barry, president, Advanced Surgical, Covidien. “These new device lengths enable surgeons to use Sonicision technology in a more diverse range of surgical procedures while avoiding the need for cords and separate generators.”

As the only cordless ultrasonic dissection device currently on the market, the Sonicision system gives surgeons complete freedom of movement in the operating room. Increased mobility eliminates the frustration of managing cords in a sterile field and helps to increase procedural efficiencies. In addition, reducing the number of cords in the operating room (OR) contributes to a safer OR and patient experience1.

The Sonicision system is used in a wide variety of general, bariatric, colorectal, gynecological and urological surgical procedures. The device’s streamlined design allows a surgeon’s eyes to remain in the surgical field rather than on the instrument. The new device lengths allow surgeons to expand their use of the Sonicision system to an increasing number of procedures, including pediatric colectomy, splenectomy, and appendectomy.

The full cordless ultrasonic portfolio is currently available in the United States. For more information on Sonicision products, visit: covidien.com/sonicision.

ABOUT COVIDIEN

Covidien is a global health care leader that understands the challenges faced by providers and their patients and works to address them with innovative medical technology solutions and patient care products. Inspired by patients and caregivers, Covidien’s team of dedicated professionals is privileged to help save and improve lives around the world. With more than 38,000 employees, Covidien operates in 150-plus countries and had 2013 revenue of $10.2 billion. To learn more about our business visit www.covidien.com or connect with us on Twitter.

1 Reduction of cords improves safety in the O.R. AORN Report: Brogmus G, Leone W, Butler L. Hernandez E [2007]. Best practices in OR suite layout and equipment choices to reduce slips, trips and falls. AORN (Association of PerOperative Registered Nurses) J86:384-398

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140918005167/en/

Source: Covidien plc

Covidien
John Jordan, 508-452-4891
Director, External Communications
john.jordan@covidien.com
or
Marguerite Copel, 203-821-4720
Vice President, Communications
marguerite.copel@covidien.com
or
Coleman Lannum, CFA, 508-452-4343
Vice President, Investor Relations
cole.lannum@covidien.com
or
Todd Carpenter, 508-452-4363
Sr. Director, Investor Relations
todd.carpenter@covidien.com